CTOs on the Move

Faraday Pharmaceuticals

www.faradaypharma.com

 
Faraday Pharmaceuticals is a biopharmaceutical company pursuing the development of elemental reducing agents (ERAs). This pioneering approach focuses on the ability of specific reduced forms of elements to improve outcomes for patients.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Faraday Pharmaceuticals raised $33M on 02/25/2017
Faraday Pharmaceuticals raised $25M on 09/20/2019

Similar Companies

Southwood Healthcare

Southwood Healthcare is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Freedom

New Freedoms 90-day reentry program inspires personal growth and accountability while treating substance abuse and other behavioral health needs.

ProUroCare

ProUroCare is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kamada

Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company`s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of six other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada`s rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma. Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency and, in addition, its intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.

Bristol-Myers Squibb Canada

Bristol-Myers Squibb Canada is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.